Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 97 Matches

Bosutinib_V18R2_Simcyp_20240624

.

Bergamottin_V19R1_AstraZeneca_20210423
CYP inhibitor found in grapefruit juice. AstraZeneca file.
Simcyp_Theophylline_V21R1_Simcyp_20220614
Theophylline Pharmacokinetics Using Virtual Non-Pregnant, Pregnant, Fetal, Breast-Feeding, and Neonatal Populations
Dihydroartemisinin (DHA)

Brand Name(s) include: D-Artepp, Artekin, Diphos, TimeQuin, Eurartesim, Duocotecxin

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

The model at-a-glance

  Absorption Model

  • First-Order

  Volume of Distribution

  • Full PBPK (Method 2)

Note: Kp scalar used

  Route of Elimination

  • UGT1A9 (50%); UGT2B7(50%)

  Perpetrator DDI

  • CYP1A2 Inhibitor

  Validation

  • Four clinical studies describing single dose exposure of DHA were used to verify the PBPK model.  100% of studies were within 2-fold, of which 75% were within 1.5-fold.  Thus, the model performance was deemed acceptable.

  Limitations

  • The model does not account for the differences in plasma fraction unbound observed in patients compared to healthy volunteers.
  • Verification needed for perpetrator DDI assessment as literature data is unavailable at this time.

  Updates in V19

  • Updated in vitro data
    • Propranolol Papp: 30 cm/s x 106
  • Converted model to full PBPK with Vss predicted through Method 2
  • Updated retrograde clearance

 

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|